SPONSOR
Hunan Province Tumor Hospital
Total Trials
9
Recruiting
9
Phases
Phase 2, Phase 3
Conditions studied: Small-cell Lung CancerNon-Small Cell Lung CancerNon-small Cell Lung CancerLung Cancer
Hunan Province Tumor Hospital is a clinical research sponsor with 9 registered studies on ClinicalTrials.gov, of which 9 are actively recruiting participants. Research covers conditions including Small-cell Lung Cancer, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Lung Cancer.
The trial portfolio spans Phase 2, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Hunan Province Tumor Hospital
How many clinical trials has Hunan Province Tumor Hospital sponsored?
ClinicalMetric currently tracks 9 clinical trials sponsored by Hunan Province Tumor Hospital, of which 9 are actively recruiting participants. These trials cover conditions including Small-cell Lung Cancer, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Hunan Province Tumor Hospital research focus on?
Hunan Province Tumor Hospital clinical trials span Small-cell Lung Cancer, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Lung Cancer. The research pipeline includes Phase 2, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Hunan Province Tumor Hospital clinical trial?
To participate in a Hunan Province Tumor Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Hunan Province Tumor Hospital trials with current recruitment status updated daily.
Clinical Trials by Hunan Province Tumor Hospital
NCT04951947 Phase 2
Recruiting
JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer
Small-cell Lung Cancer
NCT06348927 Phase 2
Recruiting
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC
Non-Small Cell Lung Cancer
NCT06477055
Recruiting
The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer
Non-small Cell Lung Cancer
NCT04324164
Recruiting
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
Non-small Cell Lung Cancer
NCT04777084 Phase 2
Recruiting
The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.
Non-Small Cell Lung Cancer
NCT06440954 Phase 2
Recruiting
Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases
Non-Small Cell Lung Cancer
NCT05014464 Phase 2
Recruiting
ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
Non-small Cell Lung Cancer
NCT06355609 Phase 2
Recruiting
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW
Non-small Cell Lung Cancer
NCT05055908 Phase 3
Recruiting
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors
Lung Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology